VST BIO Raises $45 Million in Series A Funding

VST BIO, a San Diego-based biotechnology company specializing in treatments for vascular diseases, has announced the successful closure of its Series A funding round, securing $45 million. This round was led by Coefficient Giving, a philanthropic funder with a focus on impactful scientific and global health initiatives.

Funding Details and Company Goals

The recently acquired funding is earmarked for advancing VST BIO's lead therapeutic candidate, VB-001, into first-in-human clinical studies within the year. VB-001 is a monoclonal antibody designed to target vascular inflammation and edema, showing promise in treating acute ischemic stroke, sepsis, and cytokine release syndrome.

Krisztina Zsebo, co-founder and CEO of VST BIO, expressed the company's enthusiasm for the progress: "We are pleased to have completed this financing to support advancement of VB-001 for the benefit of stroke patients."

Strategic Use of Funds

The funds will not only support the clinical trials for VB-001 but will also be used to expand VST BIO's therapeutic platform and develop its core capabilities. This strategic investment aims to bolster the company's position in the field of vascular-related conditions, particularly concerning ischemic stroke treatments.

New Board Appointment

As part of the funding round, VST BIO has appointed William Sessa to its Board of Directors. Sessa, who has an extensive background in vascular therapeutics, previously served as Senior Vice President and Chief Scientific Officer for Internal Medicine at Pfizer. His expertise is expected to guide VST BIO's next phase of growth. Michael Simons, co-founder of VST BIO, commented on Sessa’s appointment: "Bill Sessa brings decades of experience in translating vascular therapeutics from basic research to proof-of-concept clinical trials, which will be invaluable as we enter our next phase of growth."

Looking Ahead

With this substantial injection of capital, VST BIO is set to make significant strides in its research and development efforts. The company remains committed to advancing its pipeline of first-in-class antibody therapies, aiming to transform treatment options for patients with debilitating vascular conditions.